

**MISSISSIPPI DIVISION OF MEDICAID
DRUG UTILIZATION REVIEW (DUR) BOARD
MINUTES OF THE MARCH 20, 2025 MEETING**

DUR Board Roster: State Fiscal Year 2024 (July 1, 2024 – June 30, 2025)	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Joseph Austin, MD	✓		✓	✓
Amy Catherine Baggett, PharmD				✓
Terrence Brown, PharmD	✓			✓
Chrysanthia Davis, PharmD	✓	✓	✓	✓
Dena Jackson, MD		✓		✓
Jessica Lavender, MD	✓	✓		✓
Holly Moore, PharmD		✓	✓	✓
Joshua Pierce, PharmD	✓	✓		✓
Gaylen Sanders, MD	NA	✓	✓	✓
Joshua Trull, DO	✓	✓	✓	✓
Bobbie West, MD	✓			✓
TOTAL PRESENT**	8	7	5	11

*** Total Present may not be reflected by individual members marked as present above due to members who either resigned or whose terms expired being removed from the list.*

Also Present:

Division of Medicaid (DOM) Staff:

Terri Kirby, RPH, CPM, Pharmacy Director; Dennis Smith, RPH, DUR Coordinator; Amy Ly-Ha, PharmD, Pharmacist II; Anish Patel, PharmD, Pharmacist II; Catherine Brett, MD, Clinical Medical Director, Health Informatics; Amber Herron, Research/Data Analyst;

University of Mississippi School of Pharmacy - MS-DUR Staff:

Eric Pittman, PharmD, MS-DUR Project Director; Kaustuv Bhattacharya, PhD, MS-DUR Research Assistant Professor; Connor Callahan, Student Pharmacist Intern;

Coordinated Care Organization (CCO) Staff:

Jenni Grantham, PharmD, Director of Pharmacy, Magnolia Health;

Gainwell Staff:

Lew Ann Snow, RN, Advisor Business Analyst; Tricia Banks, PharmD, Director of Pharmacy;

Visitors: Cathy Prine-Eagle, Merck; Paula Whatley, Novo Nordisk; Julie Hardin, Novo Nordisk; Amanda Ellis, Boehringer;

Call to Order/Welcome:

The meeting began at 1:05 pm.

OLD BUSINESS:

Dr. Pierce moved to approve the minutes from the September 2024 and December 2024 DUR Board Meetings, seconded by Dr. Moore, and unanimously approved by the DUR Board.

Resource Utilization Review

Dr. Pittman presented the resource utilization report for December 2024. Data presented was across all pharmacy programs. Dr. Pittman took some time to compare current trends in pharmacy spend with the same time period in 2021. He noted that while current enrollment and the monthly number of prescription claims is lower than in 2021, total spend is roughly equal to that period indicating Medicaid is spending more per member monthly.

Follow-up Discussion

Dr. Pittman presented follow-up information on the most common psychotropic drug classes/molecules that were involved in adverse events among Medicaid members when concurrently prescribed with opioids. Board members discussed ways to use this information to help prevent future opioid adverse events. The discussion focused on educating members and prescribers on the potential adverse events associated with the combination of opioids and these psychotropic medications and the role of naloxone.

A motion was made by Dr. Brown, seconded by Dr. Jackson, and unanimously approved by the Board recommending Medicaid distribute naloxone education to members at increased risks of opioid related adverse events. This education could include both provider and member outreach. The Board deferred to the Pharmacy Division to make the final decision on what type of education is best suited for Medicaid members.

NEW BUSINESS:**Update on MS-DUR Educational Interventions**

Dr. Pittman provided an overview of all DUR mailings and educational notices that occurred between December 2024 and February 2025.

Compliance Measurements for Initiators of GLP-1 Anti-obesity Medications

Dr. Pittman presented the Board with an overview of the compliance for initiators of GLP-1 receptor agonist anti-obesity medications (GLP-1 RA AOMs) since their addition to the preferred drug list (PDL) in July 2023. This study estimated compliance metrics among a sample of Mississippi Medicaid members who were prescribed GLP-RA AOMs. Our study found the overall adherence rate for GLP-1 RA AOM initiators was 46.5% at 3 months and declined to 24.6% at 12 months, while persistence was 65.7% at 3 months and 33.5% at 12 months. These figures align with another recent study examining individuals in a commercial health plan. Across all of the metrics examined, Medicaid members enrolled in CCO programs were found to have better compliance compared to those enrolled in FFS. It should be noted that the impacts on medication compliance resulting from recent drug shortages of GLP-1 RAs could not be determined. Future work will reexamine compliance to GLP-1 RA AOMs post-supply chain

issues and will explore outcomes and healthcare resource utilization among individuals initiating GLP-1 RA AOMs.

The board extensively discussed the findings from this report. As the DUR team begins designing a research plan evaluating outcomes associated with GLP-1 use for obesity management, the board provided valuable insights into outcomes that should be assessed.

Impact of PMP Data on Performance on COB-AD Quality Measure

Prior to this study, it was unknown what impact incorporating MS PMP data into Medicaid prescription claims data for members would have on member monitoring parameters and routine reporting metrics related to controlled substance prescribing. This study found that incorporating MS PMP data not only increased the number of members included in the COB-AD quality measure denominator but also increased the overall rate from 3.7% to 8.0%. Further analysis revealed that factors associated with members being additionally identified in the COB-AD when MS PMP data was incorporated into claims data included being White and having a daily MME of 20 or above. Incorporating MS PMP data is critical for monitoring the appropriate prescribing of controlled substances; however, diligence should be taken in determining which routine reporting metrics should incorporate MS PMP data.

This study revealed the impact that incorporating MS PMP data into Medicaid claims data had on the COB-AD quality measure. The DUR Board considered the potential implications of incorporating MS PMP data into future controlled substance monitoring parameters and reporting by DOM, such as the high-risk beneficiaries report.

Sulfonylurea Utilization

Dr. Pittman presented the Board with a mini-report describing the utilization of sulfonylureas during calendar year 2024. Traditionally, this class of medications has not been included on the PDL. After discussing the report, the Board was in agreement to continue excluding this class from the PDL.

FDA Drug Safety Updates:

Dr. Pittman reviewed the FDA drug safety communications published between December 2024 through March 2025.

Pharmacy Program Update:

Dr. Ly-Ha presented the Board with proposed prior authorization criteria for three products: Dupixent®, Adbry®, and Journavx®. The Board provided valuable input on each of these proposed criteria.

Ms. Kirby provided a pharmacy program update:

- DOM will be launching an obesity education initiative with the goal of improving adherence and side effect management related to agents used for obesity management.
- DOM has recently updated the PDL document.

- DOM is responding to CMS' Notice of Funding Opportunity (NOFO) to participate in the Cell and Gene Therapy (CGT) Access Model.

Next Meeting Information:

Proposed meeting dates for 2025:

- June 12, 2025
- September 18, 2025
- December 11, 2025

Dr. Pierce adjourned the meeting at 3:00 pm.

Submitted,

Eric Pittman, PharmD
Evidence-Based DUR Initiative, MS-DUR

DUR Board Meeting Resources

Members

The DUR Board is composed of twelve participating Medicaid providers who are in good standing with their representative organizations.

- [DUR Board Member List](#)

Meetings

Meetings will be held on the following dates at 1:00 p.m. in the Cobb Conference Room at 550 High St, Jackson, MS ([see map](#)).

- March 20, 2025
- June 12, 2025
- September 18, 2025
- December 11, 2025

The March 20 meeting may be viewed virtually by clicking on the following link: [Click Here for MS Medicaid DUR Live Broadcast on March 20 2025 at 1:00 p.m.](#)

Please note: This link will only be live during the meeting and will not be archived for future viewing.

